000147215 001__ 147215
000147215 005__ 20240229112643.0
000147215 0247_ $$2doi$$a10.1016/S1470-2045(19)30503-0
000147215 0247_ $$2pmid$$apmid:31582354
000147215 0247_ $$2ISSN$$a1470-2045
000147215 0247_ $$2ISSN$$a1474-5488
000147215 0247_ $$2altmetric$$aaltmetric:67500436
000147215 037__ $$aDKFZ-2019-02341
000147215 041__ $$aeng
000147215 082__ $$a610
000147215 1001_ $$aHerling, Carmen D$$b0
000147215 245__ $$aTime-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.
000147215 260__ $$aLondon$$bThe Lancet Publ. Group$$c2019
000147215 3367_ $$2DRIVER$$aarticle
000147215 3367_ $$2DataCite$$aOutput Types/Journal article
000147215 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1573819976_28760
000147215 3367_ $$2BibTeX$$aARTICLE
000147215 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000147215 3367_ $$00$$2EndNote$$aJournal Article
000147215 500__ $$a20(11):1576-1586
000147215 520__ $$aTime-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.
000147215 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000147215 588__ $$aDataset connected to CrossRef, PubMed,
000147215 7001_ $$aCoombes, Kevin R$$b1
000147215 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b2$$udkfz
000147215 7001_ $$aBloehdorn, Johannes$$b3
000147215 7001_ $$aBarron, Lynn L$$b4
000147215 7001_ $$aAbrams, Zachary B$$b5
000147215 7001_ $$aMajewski, Tadeusz$$b6
000147215 7001_ $$aBondaruk, Jolanta E$$b7
000147215 7001_ $$aBahlo, Jasmin$$b8
000147215 7001_ $$aFischer, Kirsten$$b9
000147215 7001_ $$aHallek, Michael$$b10
000147215 7001_ $$aStilgenbauer, Stephan$$b11
000147215 7001_ $$aCzerniak, Bogdan A$$b12
000147215 7001_ $$aOakes, Christopher C$$b13
000147215 7001_ $$aFerrajoli, Alessandra$$b14
000147215 7001_ $$aKeating, Michael J$$b15
000147215 7001_ $$aAbruzzo, Lynne V$$b16
000147215 773__ $$0PERI:(DE-600)2035574-9$$a10.1016/S1470-2045(19)30503-0$$gp. S1470204519305030$$n11$$p1576-1586$$tThe lancet <London> / Oncology Oncology$$v20$$x1470-2045$$y2019
000147215 909CO $$ooai:inrepo02.dkfz.de:147215$$pVDB
000147215 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000147215 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000147215 9141_ $$y2019
000147215 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000147215 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000147215 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000147215 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLANCET ONCOL : 2017
000147215 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000147215 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000147215 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000147215 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000147215 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000147215 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000147215 915__ $$0StatID:(DE-HGF)9930$$2StatID$$aIF >= 30$$bLANCET ONCOL : 2017
000147215 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000147215 980__ $$ajournal
000147215 980__ $$aVDB
000147215 980__ $$aI:(DE-He78)C060-20160331
000147215 980__ $$aUNRESTRICTED